Free Trial
NASDAQ:ZBIO

Zenas BioPharma Q2 2025 Earnings Report

Zenas BioPharma logo
$16.71 +0.81 (+5.09%)
As of 04:00 PM Eastern

Zenas BioPharma EPS Results

Actual EPS
N/A
Consensus EPS
-$1.02
Beat/Miss
N/A
One Year Ago EPS
N/A

Zenas BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.25 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zenas BioPharma Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Zenas BioPharma Earnings Headlines

Zenas BioPharma Reports Q2 2025 Financial Results
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
See More Zenas BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email.

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

View Zenas BioPharma Profile

More Earnings Resources from MarketBeat